BBA
MTNB icon

Baker Bros. Advisors’s Matinas BioPharma MTNB Stock Holding History

Baker Bros. Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-41,928
Closed -$1.62M – 123
2020
Q2 		$1.62M Sell
41,928
-33,156
-44% -$1.27M 0.01% 106
2020
Q1 		$2.25M Buy
75,084
+22,437
+43% +$1.35M 0.01% 88
2019
Q4 		$5.97M Buy
52,647
+12,948
+33% +$750K 0.03% 65
2019
Q3 		$1.25M Buy
+39,699
New +$1.43M 0.01% 95

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Baker Bros. Advisors's MTNB Position: Q3 2020 in Review

Baker Bros. Advisors sold out of Matinas BioPharma (MTNB) in Q3 2020, closing a stake of 41,928 shares — an estimated $1.62M sold.

Baker Bros. Advisors first reported a position in MTNB in Q3 2019 and held it in 4 quarters. The position peaked at $5.97M in Q4 2019. 61 funds tracked by Wall St. Rank hold MTNB as of Q3 2020.

  • Baker Bros. Advisors reported no remaining Matinas BioPharma position as of Q3 2020 after selling out during the quarter.
  • Baker Bros. Advisors sold 41,928 Matinas BioPharma shares in Q3 2020, an estimated $1.62M.
  • Baker Bros. Advisors first reported a position in Matinas BioPharma in Q3 2019 and held it in 4 quarters.
  • Baker Bros. Advisors's Matinas BioPharma position peaked at $5.97M in Q4 2019.
  • 61 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2020.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.